Role of endothelin-1 in the development of a special type of cardiomyopathy

A. Zsáry, S. Szucs, T. Schneider, A. Rosta, P. Sármán, T. Fenyvesi, I. Karádi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The role of endothelin-1 (ET-1) in certain pathological states is still unclear. We have investigated the effect of anthracyclines (maximum dose, 450 mg/m2 of body surface) on left ventricular systolic and diastolic function and how it influences the level of plasma ET-1 in 21 patients (12 female and nine male) with Hodgkin and non-Hodgkin lymphoma. We also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA. Left ventricular function was analysed by echocardiography: ejection fraction (EF), velocity-time integral, E- and A-waves, E:A ratio, deceleration time (DT) and Doppler index were all measured. Statistical analysis was made by the Wilcoxon rank test. EF and serum ET-1 level decreased significantly (EF, 56.29 ± 5.0% to 48.57±5.9%, P <0.0001; ET-1, 6.45±4.0 pg/ml to 2.9±1.0 pg/ml, P <0.0001). DT increased significantly (179.8±47.8 ms to 215.5±66.7ms, P

Original languageEnglish
JournalClinical Science
Volume103
Issue numberSUPPL. 48
Publication statusPublished - Aug 2002

Fingerprint

Endothelin-1
Cardiomyopathies
Deceleration
Anthracyclines
Nonparametric Statistics
Serum
Hodgkin Disease
Left Ventricular Function
Non-Hodgkin's Lymphoma
Echocardiography
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anthracycline
  • Echocardiography
  • Ventricular function

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zsáry, A., Szucs, S., Schneider, T., Rosta, A., Sármán, P., Fenyvesi, T., & Karádi, I. (2002). Role of endothelin-1 in the development of a special type of cardiomyopathy. Clinical Science, 103(SUPPL. 48).

Role of endothelin-1 in the development of a special type of cardiomyopathy. / Zsáry, A.; Szucs, S.; Schneider, T.; Rosta, A.; Sármán, P.; Fenyvesi, T.; Karádi, I.

In: Clinical Science, Vol. 103, No. SUPPL. 48, 08.2002.

Research output: Contribution to journalArticle

Zsáry, A, Szucs, S, Schneider, T, Rosta, A, Sármán, P, Fenyvesi, T & Karádi, I 2002, 'Role of endothelin-1 in the development of a special type of cardiomyopathy', Clinical Science, vol. 103, no. SUPPL. 48.
Zsáry A, Szucs S, Schneider T, Rosta A, Sármán P, Fenyvesi T et al. Role of endothelin-1 in the development of a special type of cardiomyopathy. Clinical Science. 2002 Aug;103(SUPPL. 48).
Zsáry, A. ; Szucs, S. ; Schneider, T. ; Rosta, A. ; Sármán, P. ; Fenyvesi, T. ; Karádi, I. / Role of endothelin-1 in the development of a special type of cardiomyopathy. In: Clinical Science. 2002 ; Vol. 103, No. SUPPL. 48.
@article{ba9582dffc824b029d6c78df07e475cc,
title = "Role of endothelin-1 in the development of a special type of cardiomyopathy",
abstract = "The role of endothelin-1 (ET-1) in certain pathological states is still unclear. We have investigated the effect of anthracyclines (maximum dose, 450 mg/m2 of body surface) on left ventricular systolic and diastolic function and how it influences the level of plasma ET-1 in 21 patients (12 female and nine male) with Hodgkin and non-Hodgkin lymphoma. We also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA. Left ventricular function was analysed by echocardiography: ejection fraction (EF), velocity-time integral, E- and A-waves, E:A ratio, deceleration time (DT) and Doppler index were all measured. Statistical analysis was made by the Wilcoxon rank test. EF and serum ET-1 level decreased significantly (EF, 56.29 ± 5.0{\%} to 48.57±5.9{\%}, P <0.0001; ET-1, 6.45±4.0 pg/ml to 2.9±1.0 pg/ml, P <0.0001). DT increased significantly (179.8±47.8 ms to 215.5±66.7ms, P",
keywords = "Anthracycline, Echocardiography, Ventricular function",
author = "A. Zs{\'a}ry and S. Szucs and T. Schneider and A. Rosta and P. S{\'a}rm{\'a}n and T. Fenyvesi and I. Kar{\'a}di",
year = "2002",
month = "8",
language = "English",
volume = "103",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "SUPPL. 48",

}

TY - JOUR

T1 - Role of endothelin-1 in the development of a special type of cardiomyopathy

AU - Zsáry, A.

AU - Szucs, S.

AU - Schneider, T.

AU - Rosta, A.

AU - Sármán, P.

AU - Fenyvesi, T.

AU - Karádi, I.

PY - 2002/8

Y1 - 2002/8

N2 - The role of endothelin-1 (ET-1) in certain pathological states is still unclear. We have investigated the effect of anthracyclines (maximum dose, 450 mg/m2 of body surface) on left ventricular systolic and diastolic function and how it influences the level of plasma ET-1 in 21 patients (12 female and nine male) with Hodgkin and non-Hodgkin lymphoma. We also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA. Left ventricular function was analysed by echocardiography: ejection fraction (EF), velocity-time integral, E- and A-waves, E:A ratio, deceleration time (DT) and Doppler index were all measured. Statistical analysis was made by the Wilcoxon rank test. EF and serum ET-1 level decreased significantly (EF, 56.29 ± 5.0% to 48.57±5.9%, P <0.0001; ET-1, 6.45±4.0 pg/ml to 2.9±1.0 pg/ml, P <0.0001). DT increased significantly (179.8±47.8 ms to 215.5±66.7ms, P

AB - The role of endothelin-1 (ET-1) in certain pathological states is still unclear. We have investigated the effect of anthracyclines (maximum dose, 450 mg/m2 of body surface) on left ventricular systolic and diastolic function and how it influences the level of plasma ET-1 in 21 patients (12 female and nine male) with Hodgkin and non-Hodgkin lymphoma. We also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA. Left ventricular function was analysed by echocardiography: ejection fraction (EF), velocity-time integral, E- and A-waves, E:A ratio, deceleration time (DT) and Doppler index were all measured. Statistical analysis was made by the Wilcoxon rank test. EF and serum ET-1 level decreased significantly (EF, 56.29 ± 5.0% to 48.57±5.9%, P <0.0001; ET-1, 6.45±4.0 pg/ml to 2.9±1.0 pg/ml, P <0.0001). DT increased significantly (179.8±47.8 ms to 215.5±66.7ms, P

KW - Anthracycline

KW - Echocardiography

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=0036670972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036670972&partnerID=8YFLogxK

M3 - Article

VL - 103

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - SUPPL. 48

ER -